Evaluation of early response to concomitant chemoradiotherapy by interim 18F-FDG PET/CT imaging in patients with locally advanced oesophageal carcinomas

Purpose The best way to assess the response to chemoradiotherapy of locally advanced oesophageal carcinomas is not known. We used 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT to evaluate the metabolic response during chemoradiotherapy and tried to correlate this response to su...

Full description

Saved in:
Bibliographic Details
Published in:European journal of nuclear medicine and molecular imaging 2013-04, Vol.40 (4), p.477-485
Main Authors: Cuenca, Xavier, Hennequin, Christophe, Hindié, Elif, Rivera, Sofia, Vercellino, Laetitia, Baruch-Hennequin, Valérie, Gornet, Jean-Marc, Cattan, Pierre, Chirica, Mircea, Quéro, Laurent
Format: Article
Language:English
Subjects:
Adult
Aged
Carcinoma - diagnostic imaging
Carcinoma - therapy
Cardiology
Chemoradiotherapy
Cisplatin - therapeutic use
Disease-Free Survival
Esophageal Neoplasms - diagnostic imaging
Esophageal Neoplasms - mortality
Esophageal Neoplasms - therapy
Female
Fluorodeoxyglucose F18
Humans
Imaging
Male
Medicine
Medicine & Public Health
Middle Aged
Multimodal Imaging
Nuclear Medicine
Oncology
Original Article
Orthopedics
Positron-Emission Tomography
Radiology
Radiopharmaceuticals
Tomography, X-Ray Computed
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose The best way to assess the response to chemoradiotherapy of locally advanced oesophageal carcinomas is not known. We used 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT to evaluate the metabolic response during chemoradiotherapy and tried to correlate this response to survival. Methods Patients with biopsy-proven oesophageal carcinoma underwent FDG PET/CT with evaluation of the standardized uptake value (SUV) before any treatment (SUV1) and during chemoradiotherapy after two cycles of 5-fluorouracil (FU)/cisplatin and 20 Gy (SUV2). Metabolic response was defined as 1−(SUV2/SUV1). Surgery was discussed after 40 Gy and three cycles of chemotherapy. Results of interim PET were not considered for the therapeutic decision. Results Among 72 patients who underwent a first FDG PET/CT before any treatment, 59 (82 %) could receive the second FDG PET/CT examination. Median survival was 22.2 months with 1-year and 2-year survivals of 70 and 46 %, respectively. Nineteen patients (32 %) underwent surgery. Mean SUV1 and SUV2 were 12.3 ± 6.2 and 6 ± 4.1, respectively ( p  
ISSN:1619-7070
1619-7089
DOI:10.1007/s00259-012-2325-3